AX-2026-042967 · Adipotide · MKM lot MKM-2511-F3656

Section 1

Results

Measured against the index acceptance specification for the metabolic and mitochondrial peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 15 min gradient, 214 nm	99.39	% area	≥ 96.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.61	% area	≤ 4.0	PASS
Largest single impurity	RP-HPLC — truncated KLAKLAK repeat (−781 Da)	0.23	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	4095.6238	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, unit resolution (single quadrupole)	4095.5865	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-9.1	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	4.93	%	≤ 9.0	PASS
Counter-ion (TFA)	anion-exchange ion chromatography	7.43	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.63	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.50	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White to pale-yellow cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear with a single visible fibre	—	clear, no visible particulates	FAIL
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	3.53	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 15 min gradient	6.77	min	6.88 ± 0.35 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.19	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	51,182	—	≥ 20,000	PASS
Resolution to nearest impurity	vs disulfide-scrambled isomer	1.79	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 15 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 51,182, and skew follows the reported asymmetry factor of 1.19. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.23 % impurity against a 99.39 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Adipotide — main peak	6.77	4,830,662	99.39	—
2	truncated KLAKLAK repeat (−781 Da)	5.96	11,179	0.23	-781.512
3	trifluoroacetyl adduct (+96 Da)	7.18	9,235	0.19	+95.982
4	disulfide-scrambled isomer	6.99	4,860	0.10	0.000
5	open-chain (reduced disulfide, +2 Da)	6.24	4,374	0.09	+2.016
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 4095.6238 Da, computed from C190H332N60O43. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, unit-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 4095.5865 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
6+	683.6112	683.6050	-0.0062	9.4
5+	820.1320	820.1246	-0.0074	55.2
4+	1024.9132	1024.9039	-0.0093	100.0
3+	1366.2152	1366.2028	-0.0124	52.9
2+	2048.8192	2048.8005	-0.0187	9.3

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.30	99.39	divergence -0.54 pp vs batch median
Total impurities (% area)	1.70	0.61
Largest single impurity (% area)	not stated	0.23
Water (%)	4.0	4.93
Counter-ion (%)	not stated	7.43
Peptide content (%w/w)	not stated	not determined
Endotoxin (EU/mg)	0.22	0.50
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (ambient, 18 d) → laboratory (hand-carried, 6 d) → assay.
Assay date: 16 Jan 2026
Submitted to the index: 04 Feb 2026
Laboratory: Kestrel Bioanalytical, Melbourne, Australia
Method basis: 15 min gradient · unit-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

That the compound is not a near-isobaric alternative. Identity was confirmed at unit mass resolution, which cannot exclude species differing by 1 or 2 Da. The specific alternatives not excluded are named in the identity block above.
How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

des_gly04 Feb 2026

At 99.39 % the deletion-sequence family is at or below the reporting threshold. On a sequence with a hindered coupling that is a statement about coupling efficiency, and a good one.

ms_confirm04 Feb 2026

Purity at 99.39 % with identity confirmed on the same submission is the combination worth having. Either alone leaves a question the other answers.

aspartimide04 Feb 2026

Aspartimide formation at an Asp-Gly or Asp-Ser motif shows up as a pair of late-eluting satellites. They are not present above the reporting threshold on this trace.

Section 7

Related records

Same batch — lot MKM-2511-F3656 n=9

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042961	MKM-2511-F3656	Medutest	2026-Q1	98.97	5.40	—	Buyer-sourced	1	FAIL
AX-2026-042962	MKM-2511-F3656	PeptideMeter	2026-Q1	98.69	5.07	—	Buyer-sourced	0	PASS
AX-2026-042963	MKM-2511-F3656	VendorInvestigate	2026-Q1	98.49	5.69	100.5	Buyer-sourced	1	MARGINAL
AX-2026-042964	MKM-2511-F3656	Janoshik	2026-Q1	98.84	5.44	88.6	Buyer-sourced	1	MARGINAL
AX-2026-042965	MKM-2511-F3656	Janoshik	2026-Q1	98.73	4.85	100.4	Buyer-sourced	0	PASS
AX-2026-042966	MKM-2511-F3656	Medutest	2026-Q1	99.09	5.26	—	Buyer-sourced	0	PASS
AX-2026-042968	MKM-2511-F3656	VendorInvestigate	2026-Q1	98.83	5.52	99.4	Buyer-sourced	0	PASS
AX-2026-042969	MKM-2511-F3656	Medutest	2026-Q1	98.91	5.26	88.6	Supplier-supplied	2	MARGINAL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Adipotide records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-043019	MKM	MKM-2606-K5012	Janoshik	2026-Q3	97.61	5.77	105.1	Buyer-sourced	PASS
AX-2026-043020	MKM	MKM-2606-K5012	Medutest	2026-Q3	97.73	5.74	—	Buyer-sourced	PASS
AX-2026-043022	MKM	MKM-2606-K5012	Kestrel	2026-Q3	97.69	6.33	106.9	Buyer-sourced	PASS
AX-2026-043023	MKM	MKM-2606-K5012	Medutest	2026-Q3	97.48	5.56	103.7	Supplier-supplied	PASS
AX-2026-043024	MKM	MKM-2606-K5012	Kestrel	2026-Q3	98.61	5.07	—	Buyer-sourced	PASS
AX-2026-043021	MKM	MKM-2606-K5012	VendorInvestigate	2026-Q3	97.74	5.83	96.9	Buyer-sourced	PASS
AX-2026-043567	SIG	SIG-2603-6617	Janoshik	2026-Q2	98.54	3.08	96.6	Buyer-sourced	PASS
AX-2026-043566	SIG	SIG-2603-6617	PeptideMeter	2026-Q2	98.26	2.86	103.1	Buyer-sourced	PASS

Other recent MKM records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-042942	CJC-1295 (no DAC)	MKM-2603-V3346	Janoshik	2026-Q3	99.52	3.43	—	Supplier-supplied	PASS
AX-2026-043019	Adipotide	MKM-2606-K5012	Janoshik	2026-Q3	97.61	5.77	105.1	Buyer-sourced	PASS
AX-2026-042939	CJC-1295 (no DAC)	MKM-2603-V3346	PeptideMeter	2026-Q3	99.44	3.39	—	Buyer-sourced	PASS
AX-2026-043020	Adipotide	MKM-2606-K5012	Medutest	2026-Q3	97.73	5.74	—	Buyer-sourced	PASS
AX-2026-043022	Adipotide	MKM-2606-K5012	Kestrel	2026-Q3	97.69	6.33	106.9	Buyer-sourced	PASS
AX-2026-043023	Adipotide	MKM-2606-K5012	Medutest	2026-Q3	97.48	5.56	103.7	Supplier-supplied	PASS
AX-2026-042945	CJC-1295 (no DAC)	MKM-2603-V3346	PeptideMeter	2026-Q3	99.39	3.54	—	Laboratory-retained	PASS
AX-2026-042938	CJC-1295 (no DAC)	MKM-2603-V3346	Nordanalyt	2026-Q3	99.47	3.67	95.0	Buyer-sourced	PASS